Empagliflozin effects in patients with myocardial infarction

Empagliflozin effects in patients with ST-elevation myocardial infarction undergoing primary PCI: a randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20111206008307N42

Enrollment

100

Registered

2022-11-19

Start date

2022-11-22

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial infarction. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: Intervention group: Patients will receive 10 mg empagliflozin daily for 40 days in addition to usual treatments. Intervention 2: Control group: Patients will receive a placebo daily fo

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with STEMI undergoing primary PCI Patients aged between 18 to 80 years Consented patients

Exclusion criteria

Exclusion criteria: Pregnancy Lactation Renal failure (eGFR < 30) Hepatic failure Systolic blood pressure less than 100 mmHg Inflammatory and autoimmune diseases Diabetes mellitus Chronic heart failure Cancer Psychiatric disorders Empagliflozin contraindications History of receiving empagliflozin History of myocardial infarction Arrival more than 6 hours from symptoms onset

Design outcomes

Primary

Measure	Time frame
ST-segment resolution. Timepoint: Before and 90 min after primary percutaneous coronary intervention. Method of measurement: Electrocardiogram.;Cardiac troponin I. Timepoint: At baseline and then every 6 hours for the first 24 hours and every 12 hours to 72 hours after admission. Method of measurement: Laboratory test.;Cardiac ejection fraction. Timepoint: At baseline and 40 days after intervention. Method of measurement: Echocardiography.	—

Measure

Time frame

ST-segment resolution. Timepoint: Before and 90 min after primary percutaneous coronary intervention. Method of measurement: Electrocardiogram.;Cardiac troponin I. Timepoint: At baseline and then every 6 hours for the first 24 hours and every 12 hours to 72 hours after admission. Method of measurement: Laboratory test.;Cardiac ejection fraction. Timepoint: At baseline and 40 days after intervention. Method of measurement: Echocardiography.

—

Secondary

Measure	Time frame
High-sensitivity C-reactive protein (hs-CRP). Timepoint: Before primary percutaneous coronary intervention and at discharge. Method of measurement: Laboratory test.;Major adverse cardiac events. Timepoint: Within 40 days after primary percutaneous coronary intervention. Method of measurement: Interview.;Quality of life. Timepoint: At baseline and 40 days after primary percutaneous coronary intervention. Method of measurement: MacNew questionnaire.;TIMI flow. Timepoint: Before and after primary percutaneous coronary intervention. Method of measurement: Angiography.	—

Measure

Time frame

High-sensitivity C-reactive protein (hs-CRP). Timepoint: Before primary percutaneous coronary intervention and at discharge. Method of measurement: Laboratory test.;Major adverse cardiac events. Timepoint: Within 40 days after primary percutaneous coronary intervention. Method of measurement: Interview.;Quality of life. Timepoint: At baseline and 40 days after primary percutaneous coronary intervention. Method of measurement: MacNew questionnaire.;TIMI flow. Timepoint: Before and after primary percutaneous coronary intervention. Method of measurement: Angiography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTaher Entezari Maleki

Tabriz University of Medical Sciences

tentezari@gmail.com+98 41 3335 5983

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026